Skip to main content

Effects of very early mobilization for post-stroke patients: a systematic review and meta-analysis of randomized controlled trials

In brief

Mobilizing stroke patients within 24 hours was linked to 14% lower odds of good recovery

Across 22 randomized trials involving 3,215 patients, very early mobilization was associated with lower odds of a favorable outcome and higher mortality overall. High-dose regimens were linked to worse recovery, while low-dose regimens showed no clear difference from usual care; daily-function gains faded by 3 months, and the best timing and dose remain uncertain.

Journal
European journal of physical and rehabilitation medicine (Q1)
Published
11 November 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Zeli Zhao, Hongyun Wang, Dan Ning, Qinbing Dong, Shuhe Wang, Man Su, et al.
PMID
43012662
DOI
10.23736/S1973-9087.26.09593-6

Why clinicians should know about it

  • Picked for Neurology (clinical) (top studies of the week, 15 November 2026): RCT meta-analysis informs timing and safety of stroke mobilization

Abstract

BACKGROUND: Most stroke survivors live with long-term functional impairments. Although very early mobilization (VEM) benefits post-stroke recovery, the optimal intervention timing remains contentious and is tightly linked to intervention dosage. This study assesses the safety and efficacy of VEM initiated within 24 hours of acute stroke onset. METHODS: A systematic literature search was performed in six electronic databases, including Medline (via PubMed), EMBASE (via embase.com), the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, CINAHL, APA PsycInfo, and APA PsycArticles (via EBSCOhost), with the search period concluding on August 31st, 2025. Eligible RCTs were screened and included in the analysis. DATA ANALYSIS: Data were synthesized using RevMan 5.3 and Stata 15.0 software. Subgroup analyses were conducted based on different follow-up time points and intervention doses. The quality of evidence was evaluated using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system. RESULTS: A total of 22 RCTs involving 3215 participants were included. The meta-analysis results indicated that VEM was significantly associated with lower favorable outcomes (mRS/RS 0-2, OR=0.86, 95% CI: 0.74-0.99, P=0.04) and higher mortality (OR=1.23, 95% CI: 1.04-1.46, P<0.05), with low heterogeneity. At 3 months, VEM had worse favorable outcomes (OR=0.84, P=0.02), but no difference at other follow-up times. High-dose VEM reduced favorable outcomes (OR=0.84, P=0.04), while low-dose had no difference. ADL outcomes revealed a nonlinear prognostic effect of VEM: beneficial effects emerge at day 7 (SMD=0.73, 95% CI: 0.09, 1.37; P=0.03), peak at 1 month (SMD=1.35, 95% CI: 0.72, 1.98; P<0.0001), and decline to statistical insignificance by 3 months (SMD=0.10, 95% CI: -0.09, 0.28; P=0.30), with greater functional recovery in patients receiving high-dose regimens (SMD = 1.48, 95% CI: 0.84, 2.13; P<0.00001). No significant differences were found in mortality (dose subgroups), complications, or ADL scores between VEM and CG. CONCLUSIONS: In conclusion, high-dose VEM within 24 hours post-stroke is associated with poor functional outcomes, whereas low-dose VEM yields no between-group differences in functional recovery, mortality or complications relative to the controls. ADL benefits fail to present a linear pattern. The efficacy of VEM is modulated by multiple factors, including intervention timing, mobilization dosage, and patients' baseline clinical status. Constrained by the limited number of included trials and small sample sizes, the certainty of evidence was moderate for favorable functional outcomes, mortality and ADL, while evidence pertaining to complications was rated low. Further stratified research by baseline status, timing and dosage is necessary to define the prognostic influence of early mobilization in stroke patients.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.